Investing.com - Traws Pharma (NASDAQ: TRAW) reported third quarter EPS of $-8.810, $8.56 worse than the analyst estimate of $-0.250. Revenue for the quarter came in at $60K versus the consensus estimate of $58K.
Traws Pharma's stock price closed at $5.58. It is down -41.880% in the last 3 months and down -64.620% in the last 12 months.
Traws Pharma saw positive EPS revisions and negative EPS revisions in the last 90 days. See Traws Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Traws Pharma's Financial Health score is "weak performance".
Check out Traws Pharma's recent earnings performance, and Traws Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar